Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2B | P67870 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.30 |
| ▸ | ACACA | Q13085 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1486070 | 1.00 | CSNK2B (0.40) | CSNK2BGPR119ACACBACACA | |
| SCHEMBL12830241 | 0.91 | CSNK2B (0.39) | CSNK2BGPR119 | |
| SCHEMBL12840997 | 0.88 | — | — | |
| SCHEMBL1486088 | 0.86 | CSNK2B (0.41) | CSNK2BGPR119 | |
| SCHEMBL1486086 | 0.86 | CSNK2B (0.41) | CSNK2BGPR119 | |
| SCHEMBL12583401 | 0.85 | CSNK2B (0.35) | CSNK2BACACBACACA | |
| SCHEMBL15739950 | 0.79 | ACACB (0.35) | ACACBACACA | |
| SCHEMBL15739784 | 0.76 | GPR119 (0.34) | GPR119ACACBACACA | |
| SCHEMBL12840991 | 0.74 | — | — | |
| SCHEMBL17190175 | 0.74 | HTR4 (0.32) | ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2475652-A1 | PHARMACEUTICALLY USEFUL HETEROCYCLE-SUBSTITUTED LACTAMS | Cylene Pharmaceuticals, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| US-20110071115-A1 | PHARMACEUTICALLY USEFUL HETEROCYCLE-SUBSTITUTED LACTAMS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110071115-A1 | PHARMACEUTICALLY USEFUL HETEROCYCLE-SUBSTITUTED LACTAMS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110071115-A1 | PHARMACEUTICALLY USEFUL HETEROCYCLE-SUBSTITUTED LACTAMS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| WO-2011031979-A1 | PHARMACEUTICALLY USEFUL HETEROCYCLE-SUBSTITUTED LACTAMS | CYLENE PHARMACEUTICALS INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| WO-2011031979-A1 | PHARMACEUTICALLY USEFUL HETEROCYCLE-SUBSTITUTED LACTAMS | CYLENE PHARMACEUTICALS INC. (US) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071115-A1 | PHARMACEUTICALLY USEFUL HETEROCYCLE-SUBSTITUTED LACTAMS | PIM2, PIM1, PIM3 | CSNK2B 17/4885GPR119 2782/4885ACACB 1908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.